Research programme: cancer therapeutics - FORMA Therapeutics/Novartis

Drug Profile

Research programme: cancer therapeutics - FORMA Therapeutics/Novartis

Latest Information Update: 22 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FORMA Therapeutics
  • Developer FORMA Therapeutics; Novartis
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Cancer

Most Recent Events

  • 22 May 2012 Early research is ongoing in USA
  • 30 Jul 2009 FORMA Therapeutics and Novartis establish collaboration for small molecule drugs in Cancer
  • 13 Jan 2009 FORMA Therapeutics enters into license and option agreement thorugh the Novartis Option Fund
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top